PE-22-28
Spadin Analog PE-22-28
A synthetic analog of spadin, a natural peptide derived from the NTSR3/sortilin propeptide, that acts as a selective TREK-1 potassium channel blocker with rapid antidepressant and neuroplasticity-enhancing properties.
Mechanism of Action
PE-22-28 blocks TREK-1 (TRAAK) two-pore domain potassium channels, which are overexpressed in depression. TREK-1 blockade increases neuronal excitability in serotonergic pathways, promotes BDNF expression, and enhances hippocampal neurogenesis — producing antidepressant effects without the side effects of SSRIs.
Health Claims & Evidence
Rapid antidepressant effects via TREK-1 blockade
Promotes hippocampal neurogenesis
Enhances cognitive flexibility and learning
Short-Term Effects
Possible mood elevation and reduced anxiety based on animal data.
Long-Term Effects
Unknown in humans. Animal data suggests sustained neuroplasticity benefits.
Side Effects
Unknown in humans. Well-tolerated in animal studies.
Contraindications
Insufficient human data. Not for clinical use.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Spadin, a sortilin-derived peptide: target therapy for depression
Mazella et al. · PLoS Biology · 2010
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on PE-22-28 and related peptides, and prepare an educational research summary.
Explore Research